Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

16 Aug 2018

Abstract excerpt

Abstract The lactate transporter SLC16A1/monocarboxylate transporter 1 (MCT1) plays a central role in tumor cell energy homeostasis. In a cell-based screen, we identified a novel class of MCT1 inhibitors, including BAY-8002, which potently suppress bidirectional lactate transport. We investigated the antiproliferative activity of BAY-8002 in a panel of 246 cancer cell lines and show that hematopoietic tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30115664
DOI: 10.1158/1535-7163.mct-17-1253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistancePMID 30115664Read ↗

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer TreatmentSemantic proximity Read ↗

Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor MicroenvironmentSemantic proximity Read ↗

Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition.Semantic proximity Read ↗

Warburg effect and lactylation in cancer: mechanisms for chemoresistanceSemantic proximity Read ↗

Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survivalSemantic proximity Read ↗

Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance.Semantic proximity Read ↗

LC-mHTT-AN2 oversees lactate transport, hypoxia, and glucose homeostasis through dual regulation of MCT-1/4 in the tumor microenvironmentSemantic proximity Read ↗

Exploring monocarboxylate transporter inhibition for cancer treatmentSemantic proximity Read ↗

Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance.Semantic proximity Read ↗

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.Semantic proximity Read ↗

MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling PathwaySemantic proximity Read ↗

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.